Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XRCC5 siRNA is a research-grade small interfering RNA (siRNA) designed to silence the expression of the XRCC5 gene, which encodes the Ku80 protein. Ku80 is a critical component of the non-homologous end joining (NHEJ) pathway, responsible for repairing DNA double-strand breaks. By knocking down XRCC5, researchers can investigate its role in various biological processes, particularly in oncology. Studies have demonstrated that XRCC5 knockdown can inhibit tumor growth, migration, and invasion in cancers such as melanoma, colon cancer, and hepatocellular carcinoma, often by modulating downstream signaling pathways like PDK-1 or COX-2. While widely used in laboratory settings and available from commercial reagent suppliers like MedChemExpress and GE Dharmacon, it is not currently a clinical-stage therapeutic candidate.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on XRCC5 siRNA.